• BridgeBio Pharma CEO Neil Kumar sold 10,000 shares of common stock on Sept. 17, 2026.
• Sales priced at USD 69.01 to USD 69.57 per share.
• Holdings via the Kumar Haldea Family Irrevocable Trust fell to 495,686 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000897), on September 21, 2026, and is solely responsible for the information contained therein.